Furthermore, a clinical report on the enhancement of autologous CIK cells after treatment with PD-1 blocking antibodies in patients with advanced NSCLC provided additional evidence for this combination strategy [89]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.